
A gene edit against triglycerides and an eye risk on GLP-1 labels: four reports
4 stories this week: a one-time gene treatment for very high blood fats, a new eye warning for a widely used class of diabetes and weight-loss drugs, how far to lower blood pressure in diabetes, and the heart safety of an experimental weight-loss injection. What each result rests on and where it stops.
In 10 people with very high triglycerides, a single gene-editing infusion cut triglycerides by 63% in a month

On 9 November 2026 CRISPR Therapeutics presented early results for CTX310 at the American Heart Association Scientific Sessions. It is an experimental one-time CRISPR treatment aimed at the ANGPTL3 gene in the liver. ANGPTL3 is a liver protein involved in regulating triglyceride and cholesterol levels in the blood.
The phase 1b group included 10 adults with fasting triglycerides above 500 mg/dL, with a median starting level above 1,000 mg/dL; all had diabetes, and three had had pancreatitis. Each received a single intravenous infusion. At day 30, ANGPTL3 had fallen by 65% on average, triglycerides by 63%, non-HDL cholesterol by 51% and apolipoprotein B by 23%. The company reported no treatment-related serious adverse events, no clinically relevant rise in liver enzymes and no pancreatitis during the study. In the seven people followed for at least 90 days, the reductions held.
This is a company report of an open-label study with ten participants, no comparison group and a main readout at one month. It shows a change in blood fats, not fewer episodes of pancreatitis, heart attacks or strokes, and because the treatment is designed as a one-time, lasting change, long-term safety will take years to judge. The treatment is not approved; the FDA has given it a Regenerative Medicine Advanced Therapy designation, which speeds up review but is not an approval.
The FDA now requires a warning about a rare optic nerve condition on every GLP-1 drug

On 9 November 2026 the US FDA required the makers of all GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, tirzepatide and orforglipron, to add non-arteritic anterior ischaemic optic neuropathy (NAION) to the Warnings and Precautions section of the label. In NAION, blood flow to the front of the optic nerve drops, and vision in one eye falls suddenly and painlessly, sometimes for good.
The decision rests on an FDA meta-analysis of 126 randomised trials with 134,253 participants. It found 15 probable NAION events: 10 among people on GLP-1 drugs and 5 among those on placebo, or 6.4 versus 3.8 cases per 100,000 person-years. In real-world data on adults with type 2 diabetes, the risk on GLP-1 drugs was higher than on DPP-4 inhibitors (hazard ratio 1.43, 95% CI 1.02–2.01) but not significantly higher than on SGLT2 inhibitors (1.19, 95% CI 0.91–1.54).
The absolute risk is small, and the trial estimate rests on 15 events. Animal studies showed no mechanism, and diabetes, high blood pressure and sleep apnoea raise the risk of NAION on their own. The FDA advises people on these drugs to contact a health professional right away if vision suddenly drops or blurs in one eye; after NAION, whether to continue the drug is a decision to make with the doctor.
In 9,476 adults with type 2 diabetes, a systolic target below 120 did not reduce heart attacks and strokes

On 7 November 2026 the New England Journal of Medicine published OPTIMAL-DIABETES, an open-label randomised trial in Brazil. 9,476 adults with type 2 diabetes, raised blood pressure and high cardiovascular risk (mean age 64.7, 62% women) were assigned to a systolic target below 120 mm Hg or below 140 mm Hg.
The two groups did reach different pressures: after the first three months, average systolic pressure was 121.8 versus 135.4 mm Hg. Over a median of four years, cardiovascular death, non-fatal heart attack or stroke, or admission for unstable angina or heart failure occurred in 6.0% versus 6.7% (hazard ratio 0.90, 95% CI 0.77–1.06; P = 0.20). Serious adverse events occurred in 14.9% and 14.6%.
The confidence interval leaves room both for a modest benefit and for none, and the trial was open-label and run in one country. It was funded by Hospital Israelita Albert Einstein and the Brazilian Ministry of Health. A blood pressure target is set individually with the treating doctor.
In 5,507 adults with obesity and heart risk, an experimental weekly injection did not raise major heart events

On 9 November 2026 The Lancet published SYNCHRONIZE-CVOT, a phase 3 double-blind trial of survodutide, an experimental weekly injection that acts on both the glucagon and the GLP-1 receptors. 5,507 adults with a BMI of 27 or more and established cardiovascular disease or at least two risk factors, or with kidney disease and a BMI of 30 or more, received one of two dose levels or placebo at 524 sites in 34 countries.
Over a median of 22 months, cardiovascular death, non-fatal stroke or heart attack, coronary procedures for ischaemia or heart failure events occurred in 3.7% on survodutide and 4.1% on placebo (hazard ratio 0.89, 95% CI 0.67–1.18). That met the pre-set safety margin of 1.65: the drug did not raise this risk beyond it, but a reduction was not shown.
Nausea affected 48–49% of people on survodutide versus 12% on placebo, vomiting 32–34% versus 5%, and about one in five on survodutide stopped treatment because of digestive side effects, compared with 2% on placebo. The trial was funded by the developer, Boehringer Ingelheim. Survodutide is not approved for any use.
This article is for information only and does not replace a consultation with a doctor. Nothing in it is a recommendation to start, stop or change treatment.
Sources
CRISPR Therapeutics presents Phase 1b data for CTX310 demonstrating reductions in ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia. Company press release, 9 November 2026. crisprtx.com
FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of rare but serious eye condition. FDA Drug Safety Communication, 9 November 2026. fda.gov
Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes. N Engl J Med. Published online 7 November 2026. PMID 43001746, doi:10.1056/NEJMoa2612922, NCT04040634
Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. Published online 9 November 2026. PMID 43003106, doi:10.1016/S0140-6736(26)02140-9, NCT06077864
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchMedicine and treatmentA tau antibody missed its main Alzheimer's score
For anyone following Alzheimer's research: what a phase 2 trial found on the score clinicians use to track daily function, and which questions that result leaves open.
ResearchMedicine and treatmentEarly TB treatment and an esophageal cancer drug — plus 2 stories
4 stories this week: severe pneumonia in infants with HIV, esophageal cancer after a first treatment line, blood pressure and memory in type 2 diabetes, and a heart-rhythm ablation. Each note names who was studied and where the result stops.
Digest · 4 stories
ResearchMedicine and treatmentThe busiest minute of the day lined up with fewer deaths
For a reader who already moves on ordinary days and still cannot tell which part of that day is worth a conversation with a doctor. Inside is a comparison of people as they already were, not a plan for the next week.